Research programme: nausea and vomiting therapeutics - Solvay

Drug Profile

Research programme: nausea and vomiting therapeutics - Solvay

Alternative Names: SLV 323

Latest Information Update: 10 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay Pharmaceuticals
  • Class
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 25 Nov 2003 Preclinical trials in Nausea and vomiting in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top